Northwest Biotherapeutics Total Risk Alpha
| NWBO Stock | | | USD 0.21 -0.01 -4.55% |
The Total Risk Alpha reading for Northwest Biotherapeutics is computed from historical trading observations. Indicator reliability depends on the continuity of available trading data. Northwest Biotherapeutics has a market cap of 705.3 M, operating margin of -54.95%, current ratio of 0.1.
Correlation Analysis adds portfolio-level perspective. Monitoring Northwest Biotherapeutics within a portfolio highlights how it interacts with other holdings. All values are presented as reference data. Broader economic conditions can influence Northwest Biotherapeutics's otc stock valuation — related indicators include
signals in bureau of labor statistics.
Northwest Biotherapeutics has current Total Risk Alpha of 0.3121. The total risk alpha measures the performance of an asset by comparing its returns with those of a selected benchmark portfolio.
Total Risk Alpha | = | RFR + (ER[b] - ER[a]) | x | STD[a] / STD[b] |
| = | 0.3121 | |
| ER[a] | = | Expected return on investing in Northwest Biotherapeutics |
| ER[b] | = | Expected return on market index or selected benchmark |
| STD[a] | = | Standard Deviation of returns on Northwest Biotherapeutics |
| STD[b] | = | Standard Deviation of selected market or benchmark |
| RFR | = | Risk Free Rate of return. Typically T-Bill Rate |
Total Risk Alpha Peers Comparison
Total Risk Alpha Relative To Other Indicators
Northwest Biotherapeutics lands at
#3 in total risk alpha compared to key competitors. It is currently under evaluation in maximum drawdown compared to key competitors producing
122.86 in Maximum Drawdown for each unit of Total Risk Alpha. The spread between Maximum Drawdown and Total Risk Alpha for Northwest Biotherapeutics sits at
122.86 The benchmark portfolio represents the market risk matched to the total risk of the stock ETF or fund.
Compare Northwest Biotherapeutics to Peers
Other Technical Indicators